RU2004105956A - Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. - Google Patents

Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. Download PDF

Info

Publication number
RU2004105956A
RU2004105956A RU2004105956/04A RU2004105956A RU2004105956A RU 2004105956 A RU2004105956 A RU 2004105956A RU 2004105956/04 A RU2004105956/04 A RU 2004105956/04A RU 2004105956 A RU2004105956 A RU 2004105956A RU 2004105956 A RU2004105956 A RU 2004105956A
Authority
RU
Russia
Prior art keywords
allyloxy
bis
acetic acid
phenyl
chlorophenyl
Prior art date
Application number
RU2004105956/04A
Other languages
English (en)
Russian (ru)
Inventor
Лоне ЙЕППЕСЕН (DK)
Лоне ЙЕППЕСЕН
Пол Стенли БЕРИ (GB)
Пол Стенли БЕРИ
Йохн Патрик МОГЕНСЕН (DK)
Йохн Патрик Могенсен
Ингрид ПЕТТЕРССОН (DK)
Ингрид Петтерссон
Пер САУЕРБЕРГ (DK)
Пер Сауерберг
Original Assignee
Ново Нордиск А/С (DK)
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С (DK), Ново Нордиск А/С filed Critical Ново Нордиск А/С (DK)
Publication of RU2004105956A publication Critical patent/RU2004105956A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
RU2004105956/04A 2001-07-30 2002-07-05 Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п. RU2004105956A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101154 2001-07-30
DKPA200101154 2001-07-30

Publications (1)

Publication Number Publication Date
RU2004105956A true RU2004105956A (ru) 2005-03-27

Family

ID=8160643

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004105956/04A RU2004105956A (ru) 2001-07-30 2002-07-05 Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.

Country Status (15)

Country Link
EP (1) EP1414778A1 (fr)
JP (1) JP2004536150A (fr)
KR (1) KR20040019087A (fr)
CN (1) CN1537093A (fr)
BR (1) BR0211414A (fr)
CA (1) CA2452665A1 (fr)
CZ (1) CZ2004133A3 (fr)
HU (1) HUP0401575A2 (fr)
IL (1) IL159547A0 (fr)
MX (1) MXPA04000891A (fr)
NO (1) NO20040389L (fr)
PL (1) PL366401A1 (fr)
RU (1) RU2004105956A (fr)
WO (1) WO2003011807A1 (fr)
ZA (1) ZA200400161B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688540A (zh) 2002-09-05 2005-10-26 诺沃挪第克公司 新颖的乙烯基羧酸衍生物以及它们的治疗用途
KR20050055790A (ko) * 2002-10-28 2005-06-13 노보 노르디스크 에이/에스 Ｐｐａｒ 매개 질환의 치료에 유용한 신규 화합물
PL376718A1 (pl) * 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki, ich wytwarzanie i stosowanie
ITRM20030305A1 (it) * 2003-06-20 2004-12-21 Sigma Tau Ind Farmaceuti Preparazione di nuovi derivati di acidi fenil o fenossialchil mono e dicarbossilici utili nel trattamento dell'iperglicemia e dell'ipertrigliceridemia tipiche del diabete del tipo ii.
JP4928941B2 (ja) * 2003-09-19 2012-05-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物
EP1670744B9 (fr) 2003-09-19 2012-09-05 Janssen Pharmaceutica NV Acides 4-((phenoxyalkyl)thio)-phenoxyacetiques et analogues
WO2005105736A1 (fr) * 2004-05-05 2005-11-10 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
ME02005B (fr) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2622642C (fr) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidylpeptidase
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
KR100693132B1 (ko) * 2006-06-23 2007-03-14 동해전장 주식회사 정션박스내에 삽입된 릴레이의 동작 검사 장치
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20120168303A1 (en) * 2011-01-05 2012-07-05 Sueng-Nien Kao Salt water activated emergency lighting device
CN103467406B (zh) * 2013-09-03 2014-12-17 浙江医药高等专科学校 卤素取代的四氮唑羧酸类化合物、其制备方法和用途
CN103467407B (zh) * 2013-09-03 2015-04-22 浙江医药高等专科学校 四氮唑羧酸类化合物及其用途
CN103467405B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 一类四氮唑羧酸类化合物、其制备方法和用途
CN103467408B (zh) * 2013-09-03 2015-01-21 浙江医药高等专科学校 一类四氮唑羧酸类化合物及其用途
CN103467409B (zh) * 2013-09-03 2015-01-07 浙江医药高等专科学校 取代的四氮唑羧酸类化合物及其用途
KR20230054373A (ko) * 2020-07-22 2023-04-24 르네오 파마슈티컬스, 인크. 결정질 ppar-델타 작용제
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098690B1 (fr) * 1982-06-14 1987-09-09 Takeda Chemical Industries, Ltd. Dérivés d'acides vinylcarboxyliques, leur préparation et leur utilisation
AU2652397A (en) * 1996-05-13 1997-12-05 Nippon Shinyaku Co. Ltd. Substituted ethylene compounds and drugs
JP2002542218A (ja) * 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造および使用
CA2395298A1 (fr) * 2000-01-28 2001-08-02 Novo Nordisk A/S Derives de l'acide propionique et leur utilisation dans le traitement du diabete et de l'obesite

Also Published As

Publication number Publication date
HUP0401575A2 (hu) 2004-11-29
CN1537093A (zh) 2004-10-13
IL159547A0 (en) 2004-06-01
BR0211414A (pt) 2004-08-17
CA2452665A1 (fr) 2003-02-13
CZ2004133A3 (cs) 2004-06-16
EP1414778A1 (fr) 2004-05-06
WO2003011807A1 (fr) 2003-02-13
PL366401A1 (en) 2005-01-24
MXPA04000891A (es) 2004-05-21
NO20040389L (no) 2004-01-29
KR20040019087A (ko) 2004-03-04
ZA200400161B (en) 2004-08-18
JP2004536150A (ja) 2004-12-02

Similar Documents

Publication Publication Date Title
RU2004105956A (ru) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
RU2001131111A (ru) Новые соединения, их получение и применение
DK2278960T3 (en) DOSAGE regimen for a selective SIP1 RECEPTOR AGONIST
RU2008123000A (ru) Соединения для лечения метаболических нарушений
CA2513092A1 (fr) Composes pour le traitement de troubles metaboliques
JP2009528375A5 (fr)
JP2009531280A5 (fr)
CA2521621A1 (fr) Composes destines au traitement de troubles metaboliques
JP2009537559A5 (fr)
RU2004114875A (ru) Производные дикарбоновых кислот, их получение и терапевтическое применение
JP2008530242A5 (fr)
JP2005528393A5 (fr)
RU2003121236A (ru) Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием
JP2005538062A5 (fr)
CN101947218A (zh) 调控钙离子释放活化钙离子通道的方法
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
JP2006508030A5 (fr)
RU2010141823A (ru) Соединения и способ снижения мочевой кислоты
CA2521589A1 (fr) Composes pour le traitement de troubles metaboliques
CA2502297A1 (fr) Composes destines au traitement de troubles metaboliques
US20080051321A1 (en) Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
JP2009528275A5 (fr)
WO2013079407A1 (fr) Dérivés arylés pour lutter contre les ectoparasites
RU2006108572A (ru) Соединения для лечения метаболических нарушений
KR100608416B1 (ko) 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060728